Loading companies…

Singular Health Group Ltd ASX:SHG

0 opened or increased1 held0 reduced or exitedlatest position by manager, past 12 months90 days: 0 increased, 0 reduced. 1 managers in total.

Position history by manager 1 managersSelect a point to see the comment

Opened or increasedHeldReduced or exited Start or end of the position not reported

5 Mar 2026 to today

Commentary 1 comments

DateManagerActionSummary

5 Mar 2026SG Hiscock & CompanyHeldThe manager holds Singular Health because the Australian software company is targeting inefficiencies in the US medical imaging system, with its FDA-cleared 3DICOM platform enabling fast, secure transfer of scans across fragmented healthcare networks and addressing duplicate imaging that represents around 30% of a US$4bn annual cost burden. The company recently secured its first enterprise deployment with US physician network Provider Network Solutions and is running a pilot designed to demonstrate meaningful cost savings, potentially opening the door to a much larger national rollout. The business operates with a lean cost structure of approximately $500,000 per month in total corporate and operating costs, underpinned by high gross margins and exposure to a large US managed care market, with the critical inflection point being transition from pilot to scaled commercial deployment.

Article, price recorded $0.25

The source document link is a Pro feature

First mention by manager

Price recorded at each manager's first comment

Price at first mentionThe share price recorded when each of 1 managers first commented on SHG.

View Pro

About Singular Health Group Ltd

Healthcare, Health Care Technology

Singular Health Group (ASX:SHG), a medical imaging software company, is targeting inefficiencies in US healthcare according to SG Hiscock. In March 2026, SG Hiscock described Singular Health as an Australian software company targeting inefficiencies in the US medical imaging system, noting its FDA-cleared 3Dicom platform enables clinicians and patients to view and share medical images in 3D. Singular Health Group operates in the Healthcare sector within the Health Care Technology industry, and Thesis Tracker has captured 1 comment from 1 fund manager, SG Hiscock & Company. Founded in 2017 and headquartered in Subiaco, Perth, Singular Health develops 3Dicom, a software platform that converts medical scans such as CT and MRI into interactive 3D images for diagnosis, surgical planning and patient communication, and is commercialising its products in the United States through partnerships with radiology providers and health systems.

Market cap: $52m
Price to earnings: Loss-making
Return on equity: -90.1%
Dividend yield: 0.0%
Price to book: 4.97x
Net margin: -772.8%
52-week range: $0.16 to $0.35

Company figures as of 15 Oct 2026. For information only.

Questions

Who is investing in Singular Health Group Ltd (ASX:SHG)?

Fund managers including SG Hiscock & Company have invested in Singular Health Group Ltd (ASX:SHG).

What opportunities or catalysts do fund managers highlight for Singular Health Group Ltd?

SG Hiscock highlights Singular Health's FDA-cleared 3Dicom platform and the opportunity to address inefficiencies in US medical imaging.

What are the key risks to the Singular Health Group Ltd investment thesis, according to fund managers?

The available commentary does not set out specific risks, though Singular Health is an early-stage company dependent on US adoption and funding.

What does Singular Health Group Ltd (ASX:SHG) do?

Singular Health Group Ltd. is an Australian medical technology company founded in 2017 and headquartered in Subiaco. Specializing in advanced imaging software, the firm develops and commercializes innovative solutions under its core brands: 3Dicom, VSP, Health Academy, and GeoVR. These platforms provide specialized tools for medical visualization, surgical planning, and healthcare education. Singular Health focuses on leveraging proprietary technology to enhance diagnostic accuracy and clinical outcomes. As a technology-driven entity, the company remains dedicated to advancing its software capabilities within the global medical imaging market.

General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.

11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.

Disclaimer Terms of Use Privacy Complaints Contact

Loading…